Gunnstein Bakland
pål Nicolay Rydning,
Hege Linnerud,
JALAL MIRZAMOHAMMADI,
Tor Brommeland,
Pål Andre Rønning,
Magnus Mejlænder-Evjensvold
et al.:
Decreasing incidence of cervical spine fractures in patients with ankylosing spondylitis: a population-based study in Southeast Norway
The spine journal 2024 DOI
Sella Aarrestad Provan,
F. Ahlfors,
Gunnstein Bakland,
Yi Hu,
Eirik Kristianslund,
Eirik Ikdahl
et al.:
A validation of register-derived diagnoses of interstitial lung disease in patients with inflammatory arthritis: data from the NOR-DMARD study
Scandinavian Journal of Rheumatology 2024 DOI
Gudrun David Sigmo,
Solveig Hauge,
Karl Ove Hufthammer,
Marianne Wallenius,
Kjell Åsmund Blix Salvesen,
Anne Kjersti Nesje Daltveit
et al.:
Male patients with inflammatory joint diseases are less likely than controls to be childless: Results from a Norwegian population-based cohort study of 10 865 patients
Katarzyna Weronika Łosińska,
Are Hugo Pripp,
Gunnstein Bakland,
Bjørg Tilde Svanes Fevang,
Lene Kristin Brekke,
Ada Wierød
et al.:
Comparative Effectiveness and Persistence of SB4 and Reference Etanercept in Patients With Psoriatic Arthritis in Norway
Kaja Eriksrud Kjørholt,
Nina Paulshus Sundlisæter,
Anna-Birgitte Aga,
Joseph Sexton,
Inge Christoffer Olsen,
Hallvard Fremstad
et al.:
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial
The Lancet Rheumatology 2024 DOI
Emil E. Kvernberg Thomassen,
Inger Jorid Berg,
Eirik Kristianslund,
Anne Therese Tveter,
Gunnstein Bakland,
Laure Gossec
et al.:
Patients with axial spondyloarthritis reported willingness to use remote care and showed high adherence to electronic patient-reported outcome measures: an 18-month observational study
Mielnik Pawel,
Joseph Sexton,
Karen Minde Fagerli,
Gunnstein Bakland,
Yi Hu,
Eirik Kristianslund
et al.:
Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)
Anne Christine Bull Haaversen,
Lene Kristin Brekke,
Gunnstein Bakland,
Erik Rødevand,
Geirmund Myklebust,
Andreas P Diamantopoulos
:
Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis
Alen Brkic,
Andreas P Diamantopoulos,
Mari Hoff,
Espen A. Haavardsholm,
Bjørg Tilde Svanes Fevang,
Lene Kristin Brekke
et al.:
Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019)
Glenn Haugeberg,
Gunnstein Bakland,
Erik Rødevand,
Inger Johanne Widding Hansen,
Andreas P Diamantopoulos,
Are Hugo Pripp
:
Effectiveness and Persistence in SB4- and Reference Etanercept–Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway
Jens Vikse,
Øyvind Midtvedt,
Bjørg Tilde Svanes Fevang,
Torhild Oddveig Garen,
Øyvind Palm,
Marianne Wallenius
et al.:
Differential sensitivity of the 2020 revised comprehensive diagnostic criteria and the 2019 ACR/EULAR classification criteria across IgG4-related disease phenotypes: results from a Norwegian cohort
Mikkel Østergaard,
Ronald F Van Vollenhoven,
Anna Rudin,
Merete Lund Hetland,
Marte Schrumpf,
Dan C Nordström
et al.:
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
Inger Jorid Berg,
Anne Therese Tveter,
Gunnstein Bakland,
Sarah Hakim,
Eirik Kristianslund,
Siri Lillegraven
et al.:
Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial
Siri Lillegraven,
Nina Paulshus Sundlisæter,
Anna-Birgitte Aga,
Joseph Sexton,
Inge Christoffer Olsen,
Åse Lexberg
et al.:
Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
Alen Brkic,
Andreas P Diamantopoulos,
Espen A. Haavardsholm,
Bjørg Tilde Svanes Fevang,
Lene Kristin Brekke,
Liz Paucar Loli
et al.:
Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs
Magnhild Hammersland Dagestad,
Nils Vetti,
Per M Kristoffersen,
John Anker Henrik Zwart,
Kjersti Storheim,
Gunnstein Bakland
et al.:
Apparent diffusion coefficient values in Modic changes – interobserver reproducibility and relation to Modic type
Imane Bardan,
Karen Minde Fagerli,
Joseph Sexton,
Tore Kristian Aaserud Kvien,
Gunnstein Bakland,
Mielnik Pawel
et al.:
Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD
Ingrid Egeland Christensen,
Siri Lillegraven,
Mielnik Pawel,
Gunnstein Bakland,
Liz Paucar Loli,
Joseph Sexton
et al.:
Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
Siri Lillegraven,
Nina Beate Paulshus Sundlisæter,
Anna-Birgitte Aga,
Joseph Sexton,
Inge Christoffer Olsen,
Hallvard Fremstad
et al.:
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
Anna-Maria Hoffmann-Vold,
Håvard Halland Fretheim,
Vikas Kumar Sarna,
Imon Shoumitra Barua,
Maylen Carstens Nordgård,
Oliver Distler
et al.:
Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: Study protocol for the randomised controlled phase II ReSScue trial
Christian Bindesbøll,
Marco Garrido-Cumbrera,
Gunnstein Bakland,
Hanne Dagfinrud
:
Obesity Increases Disease Activity of Norwegian Patients with Axial Spondyloarthritis: Results from the European Map of Axial Spondyloarthritis Survey
Current Rheumatology Reports 2020 DOI
Mielnik Pawel,
Joseph Sexton,
Elisabeth Lie,
Gunnstein Bakland,
Liz Paucar Loli,
Eirik Kristianslund
et al.:
Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register
Drugs & Aging 2020 DOI
Merete Lund Hetland,
Espen A. Haavardsholm,
Anna Rudin,
Dan C. Nordström,
Michael Nurmohamed,
Bjorn Gudbjornsson
et al.:
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial
Aksel Thuv Nilsen,
Christine Karlsen,
Gunnstein Bakland,
Richard Watts,
Raashid Luqmani,
Wenche Koldingsnes
:
Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway
Rheumatology 2020 DOI
Elisabeth Gjefsen,
Lars Christian Haugli Bråten,
Guro Løvik Goll,
Monica Wigemyr,
Nils Bolstad,
Morten Valberg
et al.:
The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial
Brigitte Michelsen,
Joseph Sexton,
Ada Wierød,
Gunnstein Bakland,
Erik Rødevand,
Frode Krøll
et al.:
Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study
Seminars in Arthritis & Rheumatism 2019 DOI
Johannes Nossent,
Sylvia Sagen Johnsen,
Gunnstein Bakland
:
Disease Activity and Patient-Reported Health Measures in Relation to Cytokine Levels in Ankylosing Spondylitis
Rheumatology and therapy 2019 DOI
Hege Lynum Pedersen,
Kjersti Daae Horvei,
Dhivya Thiyagarajan,
Gudrun Norby,
Natalya Seredkina,
Gabriella Moroni
et al.:
Lupus nephritis: low urinary DNase I levels reflect loss of
renal DNase I and may be utilized as a biomarker of
disease progression
Vibeke Norvang,
Joseph Sexton,
Eirik Kristianslund,
Inge Christoffer Olsen,
Till Uhlig,
Gunnstein Bakland
et al.:
Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
Eirik Ikdahl,
Grunde Wibetoe,
Silvia Christin Hellerud Rollefstad,
Anne Salberg,
Kjetil Bergsmark,
Tore Kristian Kvien
et al.:
Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases
International Journal of Cardiology 2018 DOI
Seyed Esmaeil Dorraji,
Aud-Malin Karlsson Hovd,
Premasany Kanapathippillai,
Gunnstein Bakland,
Gro Østli Eilertsen,
Stine Figenschau
et al.:
Mesenchymal stem cells and T cells in the formation of Tertiary Lymphoid Structures in Lupus Nephritis
Grunde Wibetoe,
Eirik Ikdahl,
Silvia Christin Hellerud Rollefstad,
Inge Christoffer Olsen,
Kjetil Bergsmark,
Tore Kristian Kvien
et al.:
Discrepancies in risk age and relative risk estimations of cardiovascular disease in patients with inflammatory joint diseases
International Journal of Cardiology 2018 DOI
Eirik Ikdahl,
Silvia Christin Hellerud Rollefstad,
Grunde Wibetoe,
Anne Salberg,
Frode Krøll,
Kjetil Bergsmark
et al.:
Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: Experiences from the nationwide NOCAR project
RMD Open 2018 DOI
Julianne Elvenes,
Silje Fismen,
Gunn-Marit Lynghaug,
Gunnstein Bakland
:
A patient with spondylarthropathy treated with TNF-? inhibitors presenting with clinical findings suspicious of metastatic cancer disease
Rheumatology 2018 DOI
Gina Charlotte Hetland Brinkmann,
Vibeke Norvang,
Ellen Sauar Norli,
Lars Grøvle,
Anne Julsrud Haugen,
Åse Lexberg
et al.:
Treat to target strategy in early rheumatoid arthritis versus routine care – A comparative clinical practice study
Seminars in Arthritis & Rheumatism 2018 DOI
Brigitte Michelsen,
Till Uhlig,
Joseph Sexton,
Desirée van der Heijde,
Hilde Berner Hammer,
Eirik Kristianslund
et al.:
Health-related quality of life in patients with psoriatic and rheumatoid arthritis: Data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls
Johannes C. Nossent,
Sylvia Sagen-Johnsen,
Gunnstein Bakland
:
IL23R gene variants in relation to IL17A levels and clinical phenotype in patients with ankylosing spondylitis
Rheumatology - Advances in Practice (Rheumap) 2018 DOI
Grunde Wibetoe,
Eirik Ikdahl,
Silvia Christin Hellerud Rollefstad,
Inge Christoffer Olsen,
Kjetil Bergsmark,
Tore Kristian Kvien
et al.:
Cardiovascular disease risk profiles in inflammatory joint disease entities
Arthritis Research & Therapy 2017 DOI
Jens Vikse,
Even Lillejordet,
Karen Minde Fagerli,
Gunnstein Bakland,
Espen A. Haavardsholm
:
Spondyloartritt: en oversikt
Universitetsforlaget 2024
Jens Vikse,
Gunnstein Bakland,
Inger Jorid Berg,
Espen A. Haavardsholm
:
Aksial spondyloartritt
Universitetsforlaget 2024
Mikkel Østergaard,
Ronald van Vollenhoven,
Anna Rudin,
Merete L. Hetland,
Marte Schrumpf,
Dan Nordström
et al.:
CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONAL THERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STAR TRIAL
Annals of the Rheumatic Diseases 23. May 2022 FULLTEKST
Siri Lillegraven,
Nina Paulshus Sundlisæter,
Anna-Birgitte Aga,
Joe Sexton,
Inge Christoffer Olsen,
Hallvard Fremstad
et al.:
Drug Free Remission in Rheumatoid Arthritis: Data from the Randomized Controlled ARCTIC REWIND Trial
Arthritis & Rheumatology 2022 DOI
Siri Lillegraven,
Nina Beate Paulshus Sundlisæter,
Anna-Birgitte Aga,
Joseph Sexton,
Inge Christoffer Olsen,
Åse Lexberg
et al.:
STABLE VERSUS TAPERED AND WITHDRAWN
TREATMENT WITH TUMOR NECROSIS FACTOR
INHIBITOR IN RHEUMATOID ARTHRITIS REMISSION (ARCTIC REWIND): A RANDOMISED, OPEN-LABEL, PHASE 4, NON-INFERIORITY TRIAL
Siri Lillegraven,
Nina Beate Paulshus Sundlisæter,
Anna-Birgitte Aga,
Joseph Sexton,
Inge Christoffer Olsen,
Hallvard Fremstad
et al.:
TAPERING OF CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN SUSTAINED RHEUMATOID ARTHRITIS REMISSION: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL
Hege Lynum Pedersen,
Kjersti Daae Horvei,
Dhivya Thiyagarajan,
Gudrun Norby,
Natalya Seredkina,
Gabriella Moroni
et al.:
LUPUS NEPHRITIS: SEVERELY REDUCED URINARY DNASE I LEVELS REFLECT LOSS OF RENAL DNASE I, DISEASE PROGRESSION AND MAY REDUCE THE NEED FOR RENAL BIOPSIES
2018
Inger Myrnes Hansen,
Gunnstein Bakland
:
DISEASE ACTIVITY AND CHARACTERISTICS OF SpA-PATIENTS FULFILLING ESSG CRITERIA ONLY COMPARED TO SpAPATIENTS FULFILLING ASAS CRITERIA
Clinical and Experimental Rheumatology 2018
Inger Myrnes Hansen,
Gunnstein Bakland
:
Patients fulfilling European Spondyloarthropathy Study Group (ESSG) criteria but not Assessment of SpondyloArthritis international Society (ASAS) criteria for spondylarthritis
Scandinavian Journal of Rheumatology 2018 DOI
Espen A. Haavardsholm,
Anna-Birgitte Aga,
Inge Christoffer Olsen,
Siri Lillegraven,
Hilde Berner Hammer,
Till Uhlig
et al.:
Ultrasound in The Management of Rheumatoid Arthritis: Results from The Randomized Controlled Arctic Trial
Annals of the Rheumatic Diseases 2016 DOI
Inger Myrnes Hansen,
Gunnstein Bakland,
Øystein Thorleiv Førre
:
PLASMA CALPROTECTIN IN SPA-PATIENTS, A BIOMARKER FOR PERIPHERAL ARTHRITIS
Annals of the Rheumatic Diseases 2016 DOI
Inger Myrnes Hansen,
Gunnstein Bakland,
Øystein Thorleiv Førre
:
PLASMA CALPROTECTIN IN SPA-PATIENTS, A BIOMARKER FOR PERIPHERAL ARTHRITIS
Clinical and Experimental Rheumatology 2016
The 50 latest publications is shown on this page. See all publications in Cristin here →